Log in

NYSE:LLYEli Lilly And Co Competitors & Alternatives

$150.63
-2.37 (-1.55 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$150.20
Now: $150.63
$153.14
50-Day Range
$150.29
MA: $160.62
$169.13
52-Week Range
$101.36
Now: $150.63
$170.75
Volume2.10 million shs
Average Volume4.03 million shs
Market Capitalization$144.07 billion
P/E Ratio24.45
Dividend Yield1.97%
Beta0.21

Competitors

Eli Lilly And Co (NYSE:LLY) Vs. JNJ, PFE, MRK, ABBV, BMY, and ZTS

Should you be buying LLY stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Eli Lilly And Co, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Zoetis (ZTS).

Johnson & Johnson (NYSE:JNJ) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Johnson & Johnson and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson22.69%35.21%13.60%
Eli Lilly And Co24.48%183.80%15.63%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Johnson & Johnson and Eli Lilly And Co, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson041202.75
Eli Lilly And Co04712.75

Johnson & Johnson presently has a consensus price target of $164.2667, suggesting a potential upside of 11.77%. Eli Lilly And Co has a consensus price target of $169.7273, suggesting a potential upside of 12.68%. Given Eli Lilly And Co's higher probable upside, analysts clearly believe Eli Lilly And Co is more favorable than Johnson & Johnson.

Earnings and Valuation

This table compares Johnson & Johnson and Eli Lilly And Co's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion4.72$15.12 billion$8.6816.93
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94

Johnson & Johnson has higher revenue and earnings than Eli Lilly And Co. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 24 consecutive years and Eli Lilly And Co has increased its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

68.4% of Johnson & Johnson shares are held by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Johnson & Johnson beats Eli Lilly And Co on 9 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation & Earnings

This table compares Pfizer and Eli Lilly And Co's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.06$16.27 billion$2.9512.81
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94

Pfizer has higher revenue and earnings than Eli Lilly And Co. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pfizer and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer28.80%25.11%9.52%
Eli Lilly And Co24.48%183.80%15.63%

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.0%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and Eli Lilly And Co has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

70.2% of Pfizer shares are owned by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Pfizer and Eli Lilly And Co, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer08402.33
Eli Lilly And Co04712.75

Pfizer currently has a consensus price target of $38.8583, suggesting a potential upside of 2.83%. Eli Lilly And Co has a consensus price target of $169.7273, suggesting a potential upside of 12.68%. Given Eli Lilly And Co's stronger consensus rating and higher probable upside, analysts clearly believe Eli Lilly And Co is more favorable than Pfizer.

Volatility and Risk

Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.

Summary

Eli Lilly And Co beats Pfizer on 12 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Merck & Co., Inc. and Eli Lilly And Co, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
Eli Lilly And Co04712.75

Merck & Co., Inc. presently has a consensus target price of $94.9286, suggesting a potential upside of 17.33%. Eli Lilly And Co has a consensus target price of $169.7273, suggesting a potential upside of 12.68%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Eli Lilly And Co.

Insider and Institutional Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.1% of Eli Lilly And Co shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.22.20%52.94%16.50%
Eli Lilly And Co24.48%183.80%15.63%

Volatility & Risk

Merck & Co., Inc. has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.0%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years and Eli Lilly And Co has raised its dividend for 1 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares Merck & Co., Inc. and Eli Lilly And Co's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.59
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94

Merck & Co., Inc. has higher revenue and earnings than Eli Lilly And Co. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Eli Lilly And Co on 10 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Volatility and Risk

AbbVie has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Earnings and Valuation

This table compares AbbVie and Eli Lilly And Co's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.92$7.88 billion$8.9410.37
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94

Eli Lilly And Co has lower revenue, but higher earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie19.20%-628.57%14.66%
Eli Lilly And Co24.48%183.80%15.63%

Analyst Recommendations

This is a breakdown of recent ratings for AbbVie and Eli Lilly And Co, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie031402.82
Eli Lilly And Co04712.75

AbbVie presently has a consensus target price of $107.00, indicating a potential upside of 15.46%. Eli Lilly And Co has a consensus target price of $169.7273, indicating a potential upside of 12.68%. Given AbbVie's stronger consensus rating and higher possible upside, research analysts plainly believe AbbVie is more favorable than Eli Lilly And Co.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.1%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 1 consecutive years and Eli Lilly And Co has raised its dividend for 1 consecutive years.

Institutional and Insider Ownership

72.4% of AbbVie shares are owned by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly And Co shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eli Lilly And Co beats AbbVie on 9 of the 16 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bristol-Myers Squibb and Eli Lilly And Co, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031302.81
Eli Lilly And Co04712.75

Bristol-Myers Squibb currently has a consensus target price of $69.2857, indicating a potential upside of 9.75%. Eli Lilly And Co has a consensus target price of $169.7273, indicating a potential upside of 12.68%. Given Eli Lilly And Co's higher probable upside, analysts plainly believe Eli Lilly And Co is more favorable than Bristol-Myers Squibb.

Valuation and Earnings

This table compares Bristol-Myers Squibb and Eli Lilly And Co's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.46$3.44 billion$4.6913.46
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94

Eli Lilly And Co has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 2.9%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Eli Lilly And Co has increased its dividend for 1 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Bristol-Myers Squibb and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-1.61%28.47%10.79%
Eli Lilly And Co24.48%183.80%15.63%

Insider & Institutional Ownership

74.2% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Eli Lilly And Co shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Eli Lilly And Co beats Bristol-Myers Squibb on 10 of the 17 factors compared between the two stocks.

Eli Lilly And Co (NYSE:LLY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Earnings & Valuation

This table compares Eli Lilly And Co and Zoetis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11

Eli Lilly And Co has higher revenue and earnings than Zoetis. Eli Lilly And Co is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Dividends

Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly And Co has raised its dividend for 1 consecutive years and Zoetis has raised its dividend for 1 consecutive years.

Profitability

This table compares Eli Lilly And Co and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly And Co24.48%183.80%15.63%
Zoetis25.50%63.89%14.99%

Volatility & Risk

Eli Lilly And Co has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Eli Lilly And Co and Zoetis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly And Co04712.75
Zoetis08712.56

Eli Lilly And Co presently has a consensus target price of $169.7273, indicating a potential upside of 12.68%. Zoetis has a consensus target price of $149.00, indicating a potential downside of 5.05%. Given Eli Lilly And Co's stronger consensus rating and higher probable upside, equities research analysts clearly believe Eli Lilly And Co is more favorable than Zoetis.

Insider & Institutional Ownership

77.3% of Eli Lilly And Co shares are owned by institutional investors. Comparatively, 91.4% of Zoetis shares are owned by institutional investors. 0.1% of Eli Lilly And Co shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Eli Lilly And Co beats Zoetis on 8 of the 15 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$146.97-0.7%$386.95 billion$82.06 billion21.49Decrease in Short Interest
Pfizer logo
PFE
Pfizer
2.7$37.79-1.6%$209.99 billion$51.75 billion15.00Insider Buying
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.1$80.91-1.9%$204.64 billion$46.84 billion19.73
AbbVie logo
ABBV
AbbVie
2.4$92.67-0.3%$163.04 billion$33.27 billion19.72Decrease in Short Interest
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
1.8$63.13-2.1%$139.88 billion$26.15 billion-631.24Earnings Announcement
Analyst Report
Unusual Options Activity
Zoetis logo
ZTS
Zoetis
1.8$156.93-0.7%$75.21 billion$6.26 billion46.57Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$45.77-0.0%$27.35 billionN/A0.00Earnings Announcement
Heavy News Reporting
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.5$71.67-5.8%$14.80 billion$1.30 billion29.37Analyst Report
Increase in Short Interest
Analyst Revision
Mylan logo
MYL
Mylan
1.4$16.64-1.7%$8.67 billion$11.50 billion31.40Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.4$52.97-2.3%$7.30 billion$4.84 billion30.44Insider Buying
Decrease in Short Interest
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.6$122.67-3.0%$6.84 billion$2.16 billion53.10Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$20.40-4.7%$3.71 billion$114.62 million-8.40Earnings Announcement
Heavy News Reporting
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$59.96-1.7%$2.58 billion$421.03 million-239.84Earnings Announcement
Analyst Report
Increase in Short Interest
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.4$13.51-2.3%$1.57 billion$306.49 million14.37
Zogenix logo
ZGNX
Zogenix
1.4$24.74-0.7%$1.37 billion$3.65 million-2.60Unusual Options Activity
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$22.81-1.0%$1.22 billion$392.76 million10.51Upcoming Earnings
High Trading Volume
Omeros logo
OMER
Omeros
1.5$15.89-34.2%$871.62 million$111.81 million-9.18Earnings Announcement
Analyst Downgrade
High Trading Volume
Unusual Options Activity
Endo International logo
ENDP
Endo International
1.5$3.17-5.0%$760.70 million$2.91 billion-4.53Analyst Upgrade
Analyst Revision
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$21.06-5.9%$732.99 million$15.96 million-8.36Analyst Revision
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.57-0.4%$463.29 million$111.39 million91.40Increase in Short Interest
Analyst Revision
Lannett logo
LCI
Lannett
1.6$6.16-2.4%$248.15 million$655.41 million-7.51
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$4.37-3.2%$188.49 million$16.54 million-1.25Earnings Announcement
Analyst Upgrade
Decrease in Short Interest
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.3$3.38-0.3%$52.00 million$47.53 million-11.27
VIVUS logo
VVUS
VIVUS
1.2$0.47-11.5%$4.18 million$69.76 million-0.17Increase in Short Interest
This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.